Quiz: Respiratory Disease Pharmacology — 10 Fragen

1. What are respiratory diseases such as asthma and COPD primarily characterized by?

A. They are primarily caused by environmental pollutants with no inflammatory component.

B. They are infectious diseases caused by bacteria or viruses.

C. They are conditions involving airway narrowing and inflammation that impair breathing.

D. They are genetic disorders affecting lung development.

Answer: (C)

Erklärung

Respiratory diseases like asthma and COPD are primarily characterized by airway narrowing and inflammation, which impair breathing. These conditions involve airway obstruction and inflammatory processes, making breathing difficult. The other options either misrepresent the nature of these diseases or focus on unrelated aspects.

2. Which class of bronchodilators works by stimulating beta-2 adrenergic receptors, leading to airway smooth muscle relaxation?

A. Anticholinergics

B. Beta-2 Agonists

C. Methylxanthines

D. Leukotriene Modifiers

Answer: (B)

Erklärung

Beta-2 Agonists, such as albuterol and salmeterol, stimulate beta-2 adrenergic receptors causing relaxation of airway smooth muscle. Anticholinergics block muscarinic receptors, methylxanthines inhibit phosphodiesterase, and leukotriene modifiers block inflammatory mediators.

3. What is the mechanism of action of beta-2 agonists in bronchodilation?

A. They block muscarinic receptors on airway smooth muscle.

B. They inhibit phosphodiesterase enzymes, increasing cAMP levels.

C. They block leukotriene receptors, reducing inflammation and bronchoconstriction.

D. They stimulate beta-2 adrenergic receptors, leading to increased cAMP and muscle relaxation.

Answer: (D)

Erklärung

Beta-2 agonists work by stimulating beta-2 adrenergic receptors on bronchial smooth muscle, which activates adenylate cyclase, increasing cyclic AMP (cAMP) levels. Elevated cAMP causes relaxation of the airway smooth muscle, resulting in bronchodilation. This mechanism is distinct from anticholinergics, methylxanthines, and leukotriene receptor antagonists, which have different modes of action.

4. What is the primary action of anticholinergic inhalers like ipratropium and tiotropium in respiratory disease management?

A. Stimulate beta-2 receptors

B. Block muscarinic receptors, reducing bronchoconstriction

C. Inhibit phosphodiesterase enzymes

D. Block leukotriene receptors

Answer: (B)

Erklärung

Anticholinergics such as ipratropium and tiotropium block muscarinic acetylcholine receptors on airway smooth muscle, leading to reduced parasympathetic bronchoconstriction and bronchodilation.

5. What is the primary role of corticosteroids in the treatment of respiratory diseases like asthma?

A. To inhibit airway inflammation and reduce hyperresponsiveness

B. To block leukotriene receptors and prevent bronchoconstriction

C. To stimulate the production of inflammatory mediators in the airway

D. To relax airway smooth muscle and provide immediate bronchodilation

Answer: (A)

Erklärung

Corticosteroids primarily act by inhibiting inflammatory pathways, reducing cytokine production, and decreasing airway inflammation and hyperresponsiveness. They do not relax airway smooth muscle directly (that's the role of bronchodilators), nor do they block leukotriene receptors (that's the role of leukotriene modifiers). They also do not stimulate inflammatory mediators; instead, they suppress their production.

6. Which class of bronchodilators is characterized by the inhibition of phosphodiesterase, resulting in increased cyclic AMP levels?

A. Beta-2 Agonists

B. Anticholinergics

C. Methylxanthines

D. Leukotriene Modifiers

Answer: (C)

Erklärung

Methylxanthines like theophylline inhibit phosphodiesterase enzymes, leading to increased cyclic AMP and relaxation of airway smooth muscle. Beta-2 agonists stimulate receptors, anticholinergics block receptors, and leukotriene modifiers interfere with inflammatory mediators.

7. Which statement correctly distinguishes between short-acting and long-acting bronchodilators?

A. Short-acting agents provide quick relief; long-acting have prolonged effects for maintenance therapy.

B. Short-acting agents are used for maintenance; long-acting agents are used for rescue.

C. Both have equal duration; the distinction is based on potency.

D. Short-acting agents are only for COPD; long-acting only for asthma.

Answer: (A)

Erklärung

Short-acting bronchodilators, like albuterol, provide quick relief of symptoms (rescue), while long-acting agents like salmeterol are used regularly for maintenance therapy due to their prolonged effects.

8. Which of the following drugs is a long-acting beta-2 agonist commonly used in asthma management?

A. Albuterol

B. Salmeterol

C. Ipratropium

D. Theophylline

Answer: (B)

Erklärung

Salmeterol is a long-acting beta-2 agonist used for maintenance therapy in asthma. Albuterol is short-acting, ipratropium is an anticholinergic, and theophylline is a methylxanthine.

9. What is a key difference between inhaled corticosteroids and leukotriene modifiers in respiratory disease treatment?

A. Corticosteroids reduce inflammation; leukotriene modifiers block inflammatory mediators.

B. Corticosteroids are used for rescue; leukotriene modifiers are for acute attacks.

C. Leukotriene modifiers stimulate inflammation; corticosteroids inhibit it.

D. They have the same mechanism; both block leukotrienes.

Answer: (A)

Erklärung

Inhaled corticosteroids are anti-inflammatory agents that reduce airway inflammation, while leukotriene modifiers block leukotrienes, which are mediators involved in inflammation and bronchoconstriction.

10. Which of the following was authoritatively described as a 'chronic inflammatory airway disease' in 2023 literature?

A. Chronic Obstructive Pulmonary Disease (COPD)

B. Asthma

C. Pulmonary Fibrosis

D. Tuberculosis

Answer: (B)

Erklärung

Asthma is described as a chronic inflammatory airway disease characterized by airway hyperresponsiveness and wheezing, as noted in recent respiratory pharmacology updates.